Kornimate/medical-research-clean huggingface dataset:
neurological outcome in patients of traumatic subarachnoid haemorrhage

Conditions: Traumatic Subarachnoid Haemorrhage

Summary: traumatic brain injury is common cause of morbidity and mortality worldwide. incidence and pattern of traumatic brain injury varies in developed and developing countries. subarachnoid haemorrhage refers to blood in subarachnoid space that lies between arachnoid and piameninges, covering brain. it is often associated with concurrent intracranial injury component. individuals at higher risk for tsah are those who are at higher risk for blunt head trauma. this includes adolescents, low-income individuals, men, and individuals with a history of substance abuse. the investigators present study aims to investigate prognostic factors associated with the neurological outcome among patients of post traumatic sah.


Eligibility criteria:
inclusion criteria: * all patients of traumatic subarachnoid haemorrhage exclusion criteria: * metabolic disorder * altered coagulation profile * cardiac disease * co- morbid illness

Keywords: traumatic subarachnoid haemorrhage head trauma computed tomography
telems: feasibility of remote patient visits in ms

Conditions: Multiple Sclerosis

Summary: this trials randomizes patients with multiple sclerosis (ms, pwms) to a remote visit (via phone or videochat) or a regular outpatient visit. outcomes include satisfaction on the patients' and doctor's side.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of any type of ms * own a phone/smartphone/computer * informed consent exclusion criteria: * language barriers

Keywords: multiple sclerosis remote visits telemedicine remote patient monitoring remote monitoring
development of stimulator pneumatic for realization of evoked potential allodynic/somatosensory

Conditions: Neuropathic Pain

Summary: the stimuli used in the evoked potentials are electrical or laser. they are started and synchronized with the collection of the eeg by signals ttl (transistor-transistor logic). investigators propose to validate a pneumatic stimulator delivering the compressed air sync with the eeg. it has two advantages over existing stimuli: is capable of inducing in patients an allodynic response, excessive, painful, in response to a stimulation painless rarely obtained with laser or electrical stimuli. therefore, the pneumatic stimulation is a means to study allodynic evoked potentials unknown to date. it must be possible with a single stimulator to explore non-painful sensations and allodynic sensation , compare them with one device. the differences are the abnormal responses. this validation assumes evoked potential recording 1. somatosensory (low stimulation) then 2. allodynic (only in patients). the study therefore provides for the registration 100 potential for each of these two modalities in patients and only for the painless pneumatic modality in volunteers.


Eligibility criteria:
inclusion criteria of patients : * major patient * patient affiliated or entitled to a social security scheme * patient with neuropathic pain authenticated by the neurologist, with the presence of allodynia. * patient has given its written consent to participate in the study exclusion criteria of patients : * diseases affecting the nervous system, * diabetes, * patients who received chemotherapy * pregnant woman * nobody in emergencies * a person unable to give consent inclusion criteria of healthy volunteers : * major subject * subject affiliated or entitled to a social security scheme * subject has given its consent to participate in the study exclusion criteria of healthy volunteers : * diseases affecting the nervous system, * diabetes, * patients who received chemotherapy * pregnant woman * nobody in emergencies * a person unable to give consent
oxygen nanobubble drink impact on exercise in pulmonary fibrosis

Conditions: Pulmonary Fibrosis

Summary: approximately 1 in 5 (or 12.7 million adults) in the uk have longstanding respiratory illnesses, and 6.5 million patients report taking prescription medication to ease the burden. many patients suffer from lung tissue damage, which impairs adequate blood oxygenation and reduces blood saturations, and causes breathlessness. the current method of treatment is palliative - with the patient breathing supplemental oxygen through an oxygen cylinder and tube. this severely compromises patients' quality of life, as they are tethered to a heavy, unwieldy oxygen cylinder, limiting their ability and willingness to leave home. several recent studies in both animals and humans have indicated that orally administered oxygenated nanobubbles is a safe intervention that can improve tissue oxygenation. this randomized, double-blinded, cross-over, placebo-controlled study will evaluate the effect of an oxygen nanobubbles drink on the exercise performance of patients with chronic lung disease, such as pulmonary fibrosis. patients will conduct the 6 minute walk test (6mwt) twice, once with a placebo drink and once with the oxygen nanobubbles drink, based on a double-blind randomization protocol, and this study will evaluate the distance walked, heart rate, oxygen levels, breathlessness, and time to recovery in both cases. the investigators hypothesize that drinking the oxygen nanobubbles drink will improve the delivery of oxygen to vital organs, improving the distance a patient can cover in the 6 minute walk test by 30m, which is the minimum clinically important difference.


Eligibility criteria:
inclusion criteria: * patient is male or female, aged 18 years or above * participant is willing and able to give informed consent for participation in the study. * patients diagnosed with pulmonary fibrosis as per ats/ers guidelines, and in whom the lung fibrosis is considered the dominant cause of symptoms (i.e. no severe other disease such as copd or heart failure) * the patient must be able to walk independently without a walking stick * the patient can, in the view of their respiratory clinician, adequately participate in a 6mw test exclusion criteria: * pregnant or breast feeding * history of current neurological condition (e.g., epilepsy) * patient has consumed liquorice in the last 24 hours. * patients with tlco \<30% * patients with known unstable ischaemic heart disease or pulmonary hypertension * patients with a history of smoking in the previous 30 days * patients that are allergic or intolerant towards: liquorice, lecithin derived from soya or sunflower, citric acid, glycerol * patients with known severe renal dysfunction * patients with known severe liver dysfunction
a study of mdx-1100 in subjects with active ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to determine the safety and tolerability of the mdx-1100 regimen in subjects with active ulcerative colitis(uc) and determine the response rate at day 57 in patients administered mdx-1100.


Eligibility criteria:
inclusion criteria: * subjects with active uc on either 5-asa,corticosteroids,azathioprine(aza) and or/6-mercaptopurine(6-mp); * mayo score of 6 to 10 points with moderate to severe disease on endoscopy * subjects on the following medications; 1. prednisolone ≤ 20 mg daily (or equivalent) (dose must be stable for at least 2 weeks prior to study drug administration) 2. 5-asa (dose must be stable for at least 4 weeks prior to study drug administration) 3. aza or 6-mp (dose must be stable for at least 3 months prior to study drug administration) 4. rectal steroids or 5-asa (must have been stable for at least 4 weeks prior to study drug) exclusion criteria: * anti-tnf therapy within 8 weeks before study drug administration * contraindication to colonoscopy or sigmoidoscopy * primary or secondary immunodeficiency * autoimmune disease besides uc, with the exceptions of sjogren's syndrome or hypothyroidism * history of malignancy, excluding adequately treated and cured basal or squamous cell of the skin, or cervical carcinoma in situ * evidence of acute or chronic infection * clinically significant disease requiring medication

Keywords: ulcerative colitis, rectal bleeding
treatment of imminent haematological relapse in patients with aml and mds following allogeneic stem cell transplantation with 5-azacitidine (vidaza®)

Conditions: Myeloid Leukemia; Myelodysplastic Syndrome

Summary: efficacy and safety of 5-azacytidin in the treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling cd34-chimerism after hematopoietic stem cell transplantation.


Eligibility criteria:
inclusion criteria: screening phase: * age \> 18 years * patients with cd34+ aml or mds post-allogeneic hsct * written patient consent after consultation treatment phase * aml/mds: donor chimerism \< 80% in the cd34+ subpopulation following allogeneic hsct in patients with cd34+ aml or mds, but with no haematological relapse (blasts \< 5% in bone marrow) * leukocytes \> 3 gpt/l and platelets \> 75 gpt/l (transfusion-independent) exclusion criteria: * known intolerance to 5-azacitidine or mannitol * uncontrollable infectious disease * patients with active hepatitis b or c or hiv infection * severe hepatic function impairment (asat and alat may not be above three times the normal value) or hepatic cirrhosis, or malignant hepatic tumour * renal function impairment (creatinine \> twice the normal value, creatinine clearance \< 50 ml/min) * pregnancy or lactation * women of childbearing age, except for those who meet the following criteria: * postmenopausal (12 months natural amenorrhoea) * postoperative (6 weeks after bilateral ovarectomy with or without hysterectomy) * regular and correct use of a contraceptive method with an error rate \< 1% per year (e.g. implants, depot injections, combined oral contraceptives, intrauterine device - iud, whereby hormonal coils with a pearl index of \< 1% are safer than copper coils) * sexual abstinence * partner vasectomy * men who do not use one of the following for contraception: * sexual abstinence * post vasectomy * condoms * participation of the patient in a drug trial outside the indication of allogeneic transplantation up to four weeks before study initiation * addictive or other illnesses that prevent the person concerned from comprehending the nature and impact, as well as potentical consequences of the clinical trial * evidence that the patient may intentionally not comply with the protocol, e.g. lack of cooperation with the exception of a known allergic reaction or intolerance to 5-azacitidine, these criteria do not apply to the screening phase.

Keywords: acute myeloid leukaemia or myelodysplastic syndrome
repetitive transcranial magnetic stimulation and venlafaxine in depression

Conditions: Unipolar Depression

Summary: the purpose of this study is to assess the efficacy of add-on therapy with repetitive transcranial magnetic stimulation (rtms) and venlafaxine in the treatment of major depressive disorders compared to venlafaxine only (the optimal medication) and to rtms only.

rtms parameters : intensity of 120% of individually determined motor threshold; frequency : 1 hz; 360 impulsions; on period : 1 min; off period : 30 s.

Eligibility criteria:
inclusion criteria: * adults * clinical diagnosis of major depressive disorder (dsm-iv) * hdrs-17 items \> 20 * failure of one antidepressant treatment (efficacious doses for 6 weeks at least) exclusion criteria: * i or ii bipolar disorder * psychotic features * failure of one previous venlafaxine treatment * addiction comorbidity or schizophrenia comorbidity * involuntary hospitalization * seizures history * pregnancy or breastfeeding * somatic comorbidity able to impact on cognitive functions

Keywords: repetitive transcranial magnetic stimulation (rtms) major depressive disorders depression venlafaxine
strength training protocol in fibromyalgia women

Conditions: Fibromyalgia; Fatigue; Fatigue; Muscle, Heart; Strength Training; Stress

Summary: physical exercise is an effective tool for the prevention of various chronic diseases. fibromyalgia (fm) is a common chronic pain condition, in which patients may also experience a variety of other symptoms, including sleep disturbances, fatigue, stiffness, frequent episodes of pain and mental health problems, as well as possible gastrointestinal disorders. furthermore, according to the american college of rheumatology, such a generalised non-joint pain state occurs for at least three months in duration, predominantly in women over 50 years of age. in turn, chronic fatigue syndrome (cfs) presents as a disease characterised by persistent and debilitating fatigue lasting at least six months. the origin of fm and cfs is unknown, although alterations in the central nervous system (cns), as well as abnormalities in muscle physiology and immune/inflammatory response are suggested as the main causes. in addition, most patients with fm are sedentary and in poor physical condition, exacerbated by pain, fatigue or depression, which can limit their daily activities and affect their quality of life and work opportunities. in this regard, physical exercise is considered the most important non-pharmacological strategy for the treatment of fm; however, many clinically relevant questions remain unanswered regarding the most effective approach to exercise therapy in fm patients. therefore, the main objective of this project is to analyse the possible physical and mental benefits of a physical exercise programme in people diagnosed with fibromyalgia and/or chronic fatigue syndrome.


Eligibility criteria:
inclusion criteria: * women previously diagnosed with fibromyalgia and healthy women aged 18-75 years. * not be undertaking any physical activity or exercise programme for at least three months prior to the start of the protocol. exclusion criteria: * participants in the study may not present any other illness and/or injury at the time of the assessments that would prevent them from carrying out the activity. in the same way, those following pharmacological treatments or any type of cardiorespiratory disease will be excluded from the research.

Keywords: anxiety exercise strength training fibromyalgia healthy individuals women neuroinmunoendocrine system
the effects of exercise training in community-dwelling elderly with sleep disturbances with follow-up

Conditions: Exercise Addiction; Sleep Disorder

Summary: this study will explore the long-term effects of exercise training on body composition, cardiorespiratory fitness, and energy metabolism in the community-dwelling elderly with sleep disturbances

this project will be conducted in three years: in the first year,investigators will explore the correlation of sleep parameters, dietary behavior and body composition in community-dwelling elders. two hundred elders will be recruited to receive the actigraph accelerometer recording, sleep quality questionnaire, bio-electrical impedance analysis, heart rate variability analysis, cognitive and depression evaluation. secondly, the study will evaluate the efficacy and possible mechanisms of a 24-week exercise training for sleep disturbances patients. sixty patients with sleep disturbances elders will be randomized to exercise group or control group. participants in the exercise group will receive aerobic and resistance exercise 3 times per week for 24 weeks. the controls will receive sleep hygiene education and consultation. all measurements will be performed as described before. finally, all the 260 elders participating in this study will receive 12-month follow-up assessments to explore the longitudinal impact of sleep disturbances on cardiorespiratory function, body composition and metabolic function, and long-term effect of exercise training on sleep disturbances patients. investigators expect elders with poor sleep quality have lower level of health-related fitness and metabolic function; exercise training is effective to improve sleep quality, metabolic function and general health in the elders with sleep disturbances, and the effect can be sustained for a long period.

Eligibility criteria:
inclusion criteria: 1. community dwelling sedentary men and women who were 65 years or older exclusion criteria: 1. history of diagnostic and statistical manual diploma in social medicine, 4th. edition (dsm-iv) criteria for any major psychiatric disorder, including mania or alcohol or substance abuse 2. history of cognitive or other neurological disorders 3. other sleep disorders by history or documented on screening polysomnography (apnea index \>10, periodic leg movement arousal index \>15, or rapid eye movement (rem) behavior disorder 4. unstable or serious medical conditions or cardiopulmonary disease that contraindicate exercise 5. bmi \> 35 kg/m2 6. individual with a life expectancy of no more than 1 years or final stage of cancer

Keywords: sleep disturbance body composition energy metabolism exercise training community-dwelling elderly
dazhu rhodiola rosea capsule for coronary artery disease with angina pectoris

Conditions: Coronary Artery Disease

Summary: this study aims to evaluate the efficacy and safety of traditional chinese medicine dazhu rhodiola rosea capsule for treatment of coronary artery disease by observing angina symptoms, exercise capacity, and quality of life.


Eligibility criteria:
inclusion criteria: * age 18 to 75 years old * coronary heart disease with grade ⅱ or ⅲ stable or unstable angina (≥ 2 times per week), or residual angina-like symptoms 1 month to 1 year post percutaneous coronary intervention (pci) or 3 months to 1 year post coronary artery bypass surgery (cabg) * written informed consent exclusion criteria: * acute myocardial infarction within 1 month before admission * patients who plan to undergo revascularization in the next 3 months * congestive heart failure, acute myocarditis or pericarditis, thrombophlebitis, pulmonary embolism, or severe neurosis within 3 months prior to admission * patients with uncontrolled high blood pressure (systolic blood pressure greater than 160 mmhg or diastolic blood pressure greater than 100 mmhg), severe cardiopulmonary insufficiency (cardiac function grade ⅲ, ⅳ or left ventricular ejection fraction (lvef) \< 40%), severe arrhythmia (rapid atrial fibrillation and flutter, paroxysmal ventricular tachycardia, degree ⅱ type ⅱ and degree ⅲ atrioventricular block, etc.) * severe liver, kidney and hematopoietic system dysfunction or psychosis (serum alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 2 times the normal upper limit, or serum creatinine \> 1.5 times the normal upper limit) * history of bleeding or treatment with warfarin * implanted pacemakers * pregnant or lactating women * allergic to study drugs * legal disability (blindness, deafness, dumbness, intellectual disability, mental disability, physical disability) * patients who participated in other clinical trials within 3 months
identification of secreted markers for tumor hypoxia in patients with head and neck or lung cancers

Conditions: Head and Neck Cancer; Lung Cancer; Lip Cancer; Lip Neoplasms; Head and Neck Cancers

Summary: the purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. we have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

the endpoints of the study are 1. to validate the prognostic significance of opn in h\&n and lung cancer patients and to monitor its level during active therapy and follow up for cancer surveillance. 2. to identify a gene and protein signature for hypoxia in h\&n and lung cancer patients.

Eligibility criteria:
inclusion criteria: * histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck. * able to sign a stanford irb approved consent form exclusion criteria: * refuse or unable to sign an irb approved consent form. * refuse to be contacted in the future for follow up.
aerosure and six minute walk distance in severe copd

Conditions: COPD

Summary: to investigate whether high frequency airflow oscillation (hfao), delivered using aerosure, increases six minute walk distance (6mwd) and reduces exertional breathlessness in patients with severe chronic obstructive pulmonary disease (copd).


Eligibility criteria:
inclusion criteria: * stable severe copd (fev1 \< 50% predicted) * modified mrc dyspnoea score 2 or greater * at least 10 pack year smoking history * able to mobilise independently exclusion criteria: * contraindications to spirometry \[1\] * contraindications to clinical exercise testing \[2\] * contraindications to hfao (see section a.6.3b)) * resting spo2\>88% on air or on patient's usual oxygen prescription * systolic arterial blood pressure (abp) \>200mmhg, diastolic abp \>100 mmhg 1. cooper, b.g., an update on contraindications for lung function testing. thorax, 2010. 2. ats/accp statement on cardiopulmonary exercise testing. am. j. respir. crit. care med., 2003. 167(2): p. 211-277.
electroclinical features of sudden unexpected death in epilepsy (sudep) : a multi-center observational study

Conditions: Sudden Unexpected Death in Epilepsy; Near-Sudden Unexpected Death in Epilepsy

Summary: sudden unexpected death in epilepsy (sudep) is regarded as a leading cause of premature death in epilepsy patients. we aim to capture the whole process of sudep and near-sudep occurrence in patients with epilepsy, and expolre video-electroencephalograph (v-eeg) changes and marker. a chinese multicenter study was carried out to determine electroencephalo-graph marker related to sudep to provide a scientific basis for the prevention of sudep in patients with epilepsy.


Eligibility criteria:
inclusion criteria: * patients with epilepsy who meet sudep or near-sudep diagnosis, * giving written informed consent to participate in the study from relatives or caregivers. exclusion criteria: * refusing to recruitment from relatives or caregivers.